4/23
12:32 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
4/23
12:32 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
4/23
12:29 pm
beam
Rating for BEAM
Medium
Report
Rating for BEAM
4/23
12:29 pm
beam
Rating for BEAM
Medium
Report
Rating for BEAM
3/27
10:57 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $57.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $57.00 price target on the stock.
3/27
10:09 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
3/27
10:09 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
3/12
07:15 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
2/28
11:06 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
2/28
11:06 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
2/28
09:56 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
2/28
09:56 am
beam
Rating for BEAM
Low
Report
Rating for BEAM
2/27
05:36 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock, up previously from $48.00.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock, up previously from $48.00.
2/27
05:36 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock, up previously from $48.00.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock, up previously from $48.00.
1/29
07:08 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $40.00 price target on the stock, up previously from $38.00.
High
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $40.00 price target on the stock, up previously from $38.00.
1/29
05:42 am
beam
Rating for BEAM
High
Report
Rating for BEAM